<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/2079-701X-2016-3-66-71</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-61</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ДРУГИЕ ПРОБЛЕМЫ ЭНДОКРИНОЛОГИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>OTHER PROBLEMS OF ENDOCRINOLOGY</subject></subj-group></article-categories><title-group><article-title>Мужское здоровье при сахарном диабете 2-го типа. Фокус на метаболические и антиоксидантные свойства тестостерона</article-title><trans-title-group xml:lang="en"><trans-title>Men's health in type 2 diabetes. Focus on metabolic and antioxidant properties of testosterone</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Аметов</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Ametov</surname><given-names>А. S.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Камынина</surname><given-names>Л. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Kamynina</surname><given-names>L. L.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рождественская</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Rozhdestvenskaya</surname><given-names>O. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пашкова</surname><given-names>Е. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Pashkova</surname><given-names>E. Y.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Российская медицинская академия последипломного образования<country>Россия</country></aff><aff xml:lang="en">Russian Medical Academy of Postgraduate Education<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">Научный клинический центр ОАО «РЖД»<country>Россия</country></aff><aff xml:lang="en">Scientific Clinical Center of Russian Railways OAO<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>30</day><month>12</month><year>2016</year></pub-date><volume>0</volume><issue>3</issue><fpage>66</fpage><lpage>71</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Аметов А.С., Камынина Л.Л., Рождественская О.А., Пашкова Е.Ю., 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="ru">Аметов А.С., Камынина Л.Л., Рождественская О.А., Пашкова Е.Ю.</copyright-holder><copyright-holder xml:lang="en">Ametov  А.S., Kamynina  L.L., Rozhdestvenskaya  O.A., Pashkova  E.Y.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/61">https://www.med-sovet.pro/jour/article/view/61</self-uri><abstract><p>Окислительный стресс является патогенетической основой прогрессирования СД2. Актуальной проблемой при СД2 является оценка антиоксидантных свойств препаратов тестостерона, используемых для коррекции мужского гипогонадизма (СД2-коморбидного заболевания). Цель: оценить антиокси-дантные свойства заместительной гормональной терапии препаратами тестостерона (ЗГТПТ) у пациентов с СД2. Материалы и методы: в рандомизированное (1:1) клиническое исследование включено 108 пациентов с СД2, висцеральным ожирением и гипогонадизмом. В основной группе в течение 12 мес. проводилась ЗГТПТ. Оценивалась динамика метаболических (гликемических и внегликемиче-ских) показателей и активности ферментов антиоксидантной защиты - супероксиддисмутазы (СОД) и глутатионпероксидазы (ГПО). Для характеристики динамики окислительного стресса предложен расчетный индекс AOxS. Результаты: на фоне ЗГТПТ установлено улучшение метаболического и анти-оксидантного статуса. Повышение активности СОД и ГПО на фоне ЗГТПТ составило 32,4 ± 5,6 Ед/л и 580 ± 68 Ед/мл соответственно (p &lt; 0,05). Положительная динамика индекса AOxS отмечена только в основной группе, что свидетельствует о снижении окислительного стресса при проведении ЗГТПТ. Выводы: у пациентов с СД2 и висцеральным ожирением проведение ЗГТПТ способствует не только улучшению метаболических параметров, но и элиминации окислительного стресса и глюкозолипо-токсичности, и это может потенциально снизить риск прогрессирования СД2 и его осложнений.</p></abstract><trans-abstract xml:lang="en"><p>Oxidative stress is the pathogenetic basis for the progression of T2DM. It is important to evaluate antioxidant properties of testosterone medications used for the management of male hypogonadism (a comorbidity of T2DM). Aim: to evaluate antioxidant properties of testosterone hormone replacement therapy (THRT) in patients with type 2 diabetes. Material and methods: the randomized (1:1) clinical trial included 108 patients with type 2 diabetes, visceral obesity and hypogonadism. The treatment group received THRT for 12 months. The changes in metabolic (glycemic and non-glycemic) parameters and activity of antioxidant protection enzymes - superoxide dismutase (SOD) and glutathione peroxiase, (GPO), were evaluated. The ΔOxS index was suggested to characterize the changes in oxidative stress. Results: THRT was associated with improved metabolic and antioxidant status. Increased SOD and GPO activity against a background of THRT was 32.4 ± 5.6 U/l and 580 ± 68 U/ml, respectively (p &lt; 0.05). ΔOxS was characterized by positive changes only in the treatment group, indicating a decrease in oxidative stress during THRT. Conclusions: in patients with visceral obesity and T2DM, THRT contributed to improvement in metabolic parameters and elimination of oxidative stress and glucose-lypo-toxicity, and that could potentially reduce the risk of progression of type 2 diabetes and its complications.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>сахарный диабет 2-го типа</kwd><kwd>окислительный стресс</kwd><kwd>супероксиддисмутаза</kwd><kwd>глутатионпероксидаза</kwd><kwd>тестостерон</kwd><kwd>мужское здоровье</kwd><kwd>type 2 diabetes</kwd><kwd>oxidative stress</kwd><kwd>superoxide dismutase</kwd><kwd>glutathione peroxidase</kwd><kwd>testosterone</kwd><kwd>men's health</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Аметов А.С., Камынина ЛЛ., Ахмедова З.Г Глюкозо- и липотоксичность - взаимоотягощающие факторы при сочетании сахарного диабета типа 2 и ожирения. Врач, 2014, 4: 21-23.</mixed-citation><mixed-citation xml:lang="en">Аметов А.С., Камынина ЛЛ., Ахмедова З.Г Глюкозо- и липотоксичность - взаимоотягощающие факторы при сочетании сахарного диабета типа 2 и ожирения. Врач, 2014, 4: 21-23.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol., 2013, 169(6): 725-33.</mixed-citation><mixed-citation xml:lang="en">Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol., 2013, 169(6): 725-33.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Nieschlag E, Behre HM, Nieschlag S. Andrology. Male reproductive health and dysfunction. Internistische Praxis, 2011, 51(4): 751.</mixed-citation><mixed-citation xml:lang="en">Nieschlag E, Behre HM, Nieschlag S. Andrology. Male reproductive health and dysfunction. Internistische Praxis, 2011, 51(4): 751.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Пашкова Е.Ю., Рождественская О.А. Возрастной андрогенный дефицит у мужчин: этиология, клиника, диагностика, лечение. Андрология и генитальная хирургия, 2015, 1: 95-101.</mixed-citation><mixed-citation xml:lang="en">Пашкова Е.Ю., Рождественская О.А. Возрастной андрогенный дефицит у мужчин: этиология, клиника, диагностика, лечение. Андрология и генитальная хирургия, 2015, 1: 95-101.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Гусакова Д.А., Ефремов Е.А., Мельник Я.И., Симаков В.В. Роль окислительного стресса в патофизиологическом механизме эректильной дисфункции. Consilium Medicum, 2013, 15(7): 28-31.</mixed-citation><mixed-citation xml:lang="en">Гусакова Д.А., Ефремов Е.А., Мельник Я.И., Симаков В.В. Роль окислительного стресса в патофизиологическом механизме эректильной дисфункции. Consilium Medicum, 2013, 15(7): 28-31.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Rao PM, Kelly DM, Jones TH. Testosterone and insulin resistance in the metabolic syndrome and T2DM in men. Nat Rev Endocrinol, 2013, 9(8): 479-93.</mixed-citation><mixed-citation xml:lang="en">Rao PM, Kelly DM, Jones TH. Testosterone and insulin resistance in the metabolic syndrome and T2DM in men. Nat Rev Endocrinol, 2013, 9(8): 479-93.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">De Maddalena C, Vodo S, Petroni A, Aloisi AM. Impact of testosterone on body fat composition. J Cell Physiol, 2012, 227(12): 3744-8.</mixed-citation><mixed-citation xml:lang="en">De Maddalena C, Vodo S, Petroni A, Aloisi AM. Impact of testosterone on body fat composition. J Cell Physiol, 2012, 227(12): 3744-8.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Grossmann M. Testosterone and glucose metabolism in men: current concepts and controversies. J Endocrinol, 2014 Jan 27, 220(3): R37-55.</mixed-citation><mixed-citation xml:lang="en">Grossmann M. Testosterone and glucose metabolism in men: current concepts and controversies. J Endocrinol, 2014 Jan 27, 220(3): R37-55.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Araki E, Nishikawa T. Oxidative stress: A cause and therapeutic target of diabetic complications. J Diabetes Investig, 2010, 1(3): 90-6.</mixed-citation><mixed-citation xml:lang="en">Araki E, Nishikawa T. Oxidative stress: A cause and therapeutic target of diabetic complications. J Diabetes Investig, 2010, 1(3): 90-6.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Aprioku JS. Pharmacology of free radicals and the impact of reactive oxygen species on the testis. J Reprod Infertil, 2013, 14(4): 158-72.</mixed-citation><mixed-citation xml:lang="en">Aprioku JS. Pharmacology of free radicals and the impact of reactive oxygen species on the testis. J Reprod Infertil, 2013, 14(4): 158-72.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Yang J, Zong X, Wu G, Lin S, Feng Y, Hu J. Taurine increases testicular function in aged rats by inhibiting oxidative stress and apoptosis. Amino Acids, 2015 Aug, 47(8): 1549-58.</mixed-citation><mixed-citation xml:lang="en">Yang J, Zong X, Wu G, Lin S, Feng Y, Hu J. Taurine increases testicular function in aged rats by inhibiting oxidative stress and apoptosis. Amino Acids, 2015 Aug, 47(8): 1549-58.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Higuchi M, Celino FT, Shimizu-Yamaguchi S, Miura C, Miura T. Taurine plays an important role in the protection of spermatogonia from oxida-tive stress. Amino Acids, 2012, 43(6): 2359-69.</mixed-citation><mixed-citation xml:lang="en">Higuchi M, Celino FT, Shimizu-Yamaguchi S, Miura C, Miura T. Taurine plays an important role in the protection of spermatogonia from oxida-tive stress. Amino Acids, 2012, 43(6): 2359-69.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Fatani AJ, Al-Rejaie SS, Abuohashish HM, Al-Assaf A, Parmar MY, Ahmed MM. Lutein dietary supplementation attenuates streptozo-tocin-induced testicular damage and oxidative stress in diabetic rats. BMC Complement Altern Med, 2015. 15: 204.</mixed-citation><mixed-citation xml:lang="en">Fatani AJ, Al-Rejaie SS, Abuohashish HM, Al-Assaf A, Parmar MY, Ahmed MM. Lutein dietary supplementation attenuates streptozo-tocin-induced testicular damage and oxidative stress in diabetic rats. BMC Complement Altern Med, 2015. 15: 204.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Tsang CK, Liu Y, Thomas J, Zhang Y, Zheng XF. Superoxide dismutase 1 acts as a nuclear transcription factor to regulate oxidative stress resistance. Nat Commun, 2014 Mar 19, 5: 3446.</mixed-citation><mixed-citation xml:lang="en">Tsang CK, Liu Y, Thomas J, Zhang Y, Zheng XF. Superoxide dismutase 1 acts as a nuclear transcription factor to regulate oxidative stress resistance. Nat Commun, 2014 Mar 19, 5: 3446.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang L, Wu S, Ruan Y, Hong L, Xing X, Lai W. Testosterone suppresses oxidative stress via androgen receptor-independent pathway in murine cardiomyocytes. Mol Med Rep, 2011, 4(6): 1183-8.</mixed-citation><mixed-citation xml:lang="en">Zhang L, Wu S, Ruan Y, Hong L, Xing X, Lai W. Testosterone suppresses oxidative stress via androgen receptor-independent pathway in murine cardiomyocytes. Mol Med Rep, 2011, 4(6): 1183-8.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Тишова Ю.А., Калинченко С.Ю. Роль коррекции гипогонадизма в лечении метаболического синдрома у мужчин и аспекты безопасности терапии препаратом тестостерона пролонгированного действия (результаты двойного слепого рандомизированного плацебо-контролируемого исследования). Ожирение и метаболизм, 2010, 26: 36-43.</mixed-citation><mixed-citation xml:lang="en">Тишова Ю.А., Калинченко С.Ю. Роль коррекции гипогонадизма в лечении метаболического синдрома у мужчин и аспекты безопасности терапии препаратом тестостерона пролонгированного действия (результаты двойного слепого рандомизированного плацебо-контролируемого исследования). Ожирение и метаболизм, 2010, 26: 36-43.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Ametov AS, Kamynina L.L., Akhmedova Z.G. Glucose- and lipo-toxicity - mutual confounding factors in type 2 diabetes mellitus combined with obesity. Vrach, 2014, 4: 21-23.</mixed-citation><mixed-citation xml:lang="en">Ametov AS, Kamynina L.L., Akhmedova Z.G. Glucose- and lipo-toxicity - mutual confounding factors in type 2 diabetes mellitus combined with obesity. Vrach, 2014, 4: 21-23.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Pashkova E.Y., Rozhdestvenskaya O.A. Age-dependent androgen deficiency in men: etiology, clinical pattern, diagnosis and treatment. Andrologiya i Genitalnaya Khirurgiya, 2015, 1: 95-101.</mixed-citation><mixed-citation xml:lang="en">Pashkova E.Y., Rozhdestvenskaya O.A. Age-dependent androgen deficiency in men: etiology, clinical pattern, diagnosis and treatment. Andrologiya i Genitalnaya Khirurgiya, 2015, 1: 95-101.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Gusakova D.A., Efremov E.A., Melnik Y.I., Simakov V.V. The role of oxidative stress in the pathophysiological mechanisms of erectile dysfunction. Consilium Medicum, 2013, 15(7): 28-31.</mixed-citation><mixed-citation xml:lang="en">Gusakova D.A., Efremov E.A., Melnik Y.I., Simakov V.V. The role of oxidative stress in the pathophysiological mechanisms of erectile dysfunction. Consilium Medicum, 2013, 15(7): 28-31.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Tishova Y.A., Kalinchenko S.Y. The role of managing hypogonadism in the treatment of metabolic syndrome in men and safety aspects of long-acting testosterone therapy (results of a randomized, double-blind, placebo-controlled study). Ozhirenie i Metabolizm, 2010, 26: 36-43.</mixed-citation><mixed-citation xml:lang="en">Tishova Y.A., Kalinchenko S.Y. The role of managing hypogonadism in the treatment of metabolic syndrome in men and safety aspects of long-acting testosterone therapy (results of a randomized, double-blind, placebo-controlled study). Ozhirenie i Metabolizm, 2010, 26: 36-43.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
